Companies view Sunshine differently

Share this article:
Pfizer
Pfizer

A report by PMLive indicates that pharmaceutical companies have distinct views on what the Sunshine Act requires.

According to a presentation made at the International Society for Medical Publications Professionals, PMLive noted, for example, that Pfizer and AstraZeneca report payments for medical writing. The companies said they report the payments because the publications represent value for the company and author.

Shire's publications director Antonia Panayi, though, said her company does not consider these publications reportable because the value is limited to pharma, as opposed to being beneficial for professionals.

Panayi said the value is limited to “what has already been paid as part of their contractual agreement for the trial,” and that author “kudos” for publication would be difficult to quantify.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.